Does Iliopsoas Lengthening Adversely Affect Clinical Outcomes After Hip Arthroscopy? A Multicenter Comparative Study
Authors: Maldonado DR, Krych AJ, Levy BA, Hartigan DE, Laseter JR, Domb BG
Journal: Am J Sports Med. 2018 Sep;46(11):2624-2631.
DOI: 10.1177/0363546518785966 | PMID: 30074842
Background:
Iliopsoas fractional lengthening (IFL) is frequently performed during hip arthroscopy to address internal snapping and femoroacetabular impingement (FAI). Concerns exist about its potential impact on clinical outcomes.
Methods:
Multicenter retrospective review comparing patients undergoing hip arthroscopy with or without IFL. Patient-reported outcomes (PROs) were collected with at least 2-year follow-up.
Key Findings:
- Both groups experienced significant improvements in pain, function, and satisfaction.
- No significant differences in revision surgery rates or conversions to total hip arthroplasty (THA) between groups.
- IFL did not adversely affect mid-term clinical outcomes.
Conclusions:
Iliopsoas lengthening during hip arthroscopy is a safe adjunct procedure that does not compromise patient outcomes when properly indicated.
What Does This Mean for Providers?
Providers can consider iliopsoas fractional lengthening as a viable component of hip arthroscopy in patients with internal snapping or impingement without fearing negative impacts on long-term outcomes. Careful patient selection remains critical to maximize benefits.